The discovery of BRCA gene by Mary-Claire King in 1990 has enlightened the understanding of hereditary breast and ovarian cancer. In the past 30 years there has been development of both preventive strategies and increased therapeutic options.

The discovery of PARP (poly adenosine diphosphate [ADP]–ribose polymerase) inhibitors are an added therapeutic armamentarium in both breast and ovarian cancers.